Lyell Immunopharma Inc [LYEL] stock is trading at $0.70, up 6.17%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The LYEL shares have gain 20.40% over the last week, with a monthly amount glided 21.75%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lyell Immunopharma Inc [NASDAQ: LYEL] stock has seen the most recent analyst activity on October 30, 2024, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $1 from $6. Previously, H.C. Wainwright downgraded its rating to Neutral on June 27, 2024, and dropped its price target to $1. On August 28, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $5 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and decreased its price target to $7 on November 14, 2022. Goldman downgraded its rating to a Neutral and reduced its price target to $7 on November 11, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on October 17, 2022, and assigned it a price target of $12. In a note dated July 12, 2021, Morgan Stanley initiated an Overweight rating and provided a target price of $25 on this stock.
Lyell Immunopharma Inc [LYEL] stock has fluctuated between $0.51 and $3.26 over the past year. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Lyell Immunopharma Inc [NASDAQ: LYEL] shares were valued at $0.70 at the most recent close of the market. An investor can expect a potential return of 42.86% based on the average LYEL price forecast.
Analyzing the LYEL fundamentals
Lyell Immunopharma Inc [NASDAQ:LYEL] reported sales of 0.06M for the trailing twelve months, which represents a growth of 36.00%. Gross Profit Margin for this corporation currently stands at -236.81% with Operating Profit Margin at -3488.44%, Pretax Profit Margin comes in at -3237.92%, and Net Profit Margin reading is -3237.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.35 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6714 points at the first support level, and at 0.6420 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7287, and for the 2nd resistance point, it is at 0.7566.
Ratios To Look Out For
For context, Lyell Immunopharma Inc’s Current Ratio is 13.43. In addition, the Quick Ratio stands at 13.43 and the Cash Ratio stands at 2.99. Considering the valuation of this stock, the price to sales ratio is 3412.00, the price to book ratio is 0.34.
